Acrux Limited Issues Director Placement Shares

Maximize Your Portfolio with Data Driven Insights:

• Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
• Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio

Acrux Limited ( (AU:ACR) ) just unveiled an update.

Acrux Limited has announced the issuance of 3,714,284 fully paid ordinary shares to its directors, following shareholder approval at an Extraordinary General Meeting earlier in February. These Director Placement Shares were issued under the same terms and conditions as previous shares from the Share Placement and Share Purchase Plan announced in December 2024. The company has complied with the relevant provisions of the Corporations Act and confirms that there is no excluded information related to this issuance.

More about Acrux Limited

Acrux is a specialty pharmaceutical company that focuses on developing and commercializing topically applied pharmaceutical products. With 25 years of experience, the company has marketed several products globally through licensees, particularly emphasizing the United States market. Acrux is involved in formulating and developing a range of topical generic products, utilizing its skilled workforce, advanced laboratories, and GMP manufacturing suite to deliver affordable products. The company is open to collaboration and is well-positioned for commercial partnerships and product development opportunities.

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $7.86M

For detailed information about ACR stock, go to TipRanks’ Stock Analysis page.